EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy

Raefa Abou Khouzam iD, Shaima Salman iD, Jerome Thiery iD, Rania Faouzi Zaarour iD, Visar Vela, Perparim Limani iD, Bassam Janji iD, Salem Chouaib

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27093873 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Raefa Abou Khouzam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman 4184, United Arab Emirates. Hauptthemen laut MEDLINE: Tumor Microenvironment, Pancreatic Neoplasms, Immunotherapy, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers, with a 5-year survival rate of 13% and broad resistance to therapy. It is driven by severe tumor hypoxia from desmoplasia, aberrant vasculature, and high interstitial pressure. Hypoxia stabilizes hypoxia-inducible factors (HIFs), reshaping the tumor microenvironment (TME) into a nutrient-poor, acidic milieu that fosters immune exclusion and suppression. While immune checkpoint inhibitors (ICIs) have revolutionized treatment, PDAC responses have been negligible. As hypoxia centrally drives PDAC’s ICI-refractory TME, targeted alleviation could offer synergy with ICIs; however, no such combination is being applied in the clinic. One impediment could be the one-size-fits-all approach when investigating hypoxia-modifying therapy. Indeed, using hypoxia gene signatures, we and others have shown that PDAC tumors are not equally hypoxic, with patients having more hypoxic tumors experiencing worse survival and immunosuppressed TME. This review dissects hypoxia’s mechanistic role in PDAC immune evasion and gives an update on the therapeutic advances that directly or indirectly target hypoxia, such as the inhibition of HIFs, hypoxia-activated prodrugs, and vascular and oxygen delivery approaches, with emphasis on their potential to enhance responses to ICIs. It further evaluates the need for hypoxia biomarkers and proposes gene signatures as detection tools to enable precision hypoxia modulation, potentially converting immune-cold PDAC into an ICI-responsive disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentPancreatic NeoplasmsImmunotherapyCarcinoma, Pancreatic DuctalTumor HypoxiaHumansAnimals

Stichwörter der Autor:innen

hypoxiahypoxia alleviationhypoxia gene signatureshypoxia targetingimmunosuppressionimmunotherapypancreatic cancer

Autor:innen und Institutionen

  • Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman 4184, United Arab Emirates.
  • Armstrong Oxygen Biology Research Center and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • INSERM UMR 1356, Next-Generation Immuno-Oncology Research and Therapy in Pediatric and Adult Cancer, Gustave Roussy, Faculty of Medicine, University Paris-Saclay, 94805 Villejuif, France.
  • Gastrointestinal Research Unit, Department of General Surgery and Surgical Oncology, Cantonal Hospital Aarau, Tellstrasse 25, CH-5001 Aarau, Switzerland.
  • Swiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.
  • Department of Surgery & Transplantation, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.

ORCID-Profile: Raefa Abou Khouzam, Shaima Salman, Jerome Thiery, Rania Faouzi Zaarour, Perparim Limani, Bassam Janji

Zitieren

APA

Abou Khouzam, R., Salman, S., Thiery, J., Zaarour, R. F., Vela, V., Limani, P., Janji, B., & Chouaib, S. (2026). Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27093873

Vancouver

Abou Khouzam R, Salman S, Thiery J, Zaarour RF, Vela V, Limani P, et al. Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27093873

BibTeX
@article{AbouKhouzam2026,
  author = {Abou Khouzam, Raefa and Salman, Shaima and Thiery, Jerome and Zaarour, Rania Faouzi and Vela, Visar and Limani, Perparim and Janji, Bassam and Chouaib, Salem},
  title = {Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27093873}
}
Kostenlos starten →